Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHELIVER Phase IIb study of HepaStem in acute-on-chronic liver failure
2019-003051-11Phase 2Active
- Sponsor
- Promethera Therapeutics
- Start
- Oct 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute-on-chronic liver failure (ACLF) comparing HepaStem with Placebo (2 arms). Primary endpoint: Survival at Day 90. Started Oct 2019; status: active.
02
Drugs
hepastem
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on 2019-003051-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003051-11.